Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine | Business

0


CAMBRIDGE, Mass .– (BUSINESS WIRE) – Sep 24, 2021–

Moderna, Inc. (Nasdaq: MRNA), a pioneering biotechnology company in messenger RNA (mRNA) therapies and vaccines, today announced a supply agreement with the government of Peru for 20 million doses of Moderna’s COVID-19 vaccine to begin delivery in the first quarter of 2022. Moderna’s COVID-19 vaccine is currently not approved for use in Peru, and the Company will work with regulators to obtain necessary approvals before distribution.

“We appreciate the support of the Government of Peru with this agreement to supply Moderna COVID-19 vaccine doses,” said Corinne Le Goff, Pharm.D., MBA, Commercial Director of Moderna. “We are committed to making our vaccine available worldwide as we seek to fight the pandemic with our COVID-19 vaccine. “

About Moderna

In the 10 years since its inception, Moderna has grown from a company in the scientific research stage advancing programs in the field of messenger RNA (mRNA), to a company with a diverse clinical portfolio of vaccines and therapeutic products. through six modalities, a broad portfolio of intellectual property in areas such as the formulation of mRNA and lipid nanoparticles, and an integrated manufacturing facility that enables both clinical and commercial production on a large scale and at low speed. previous. Moderna maintains alliances with a wide range of domestic and foreign government and business collaborators, which has allowed the pursuit of both groundbreaking science and rapid scale up of manufacturing. More recently, Moderna’s capabilities have come together to enable the licensed use of one of the oldest and most effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has enabled the development of therapies and vaccines for them. infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna was named one of the top biopharmaceutical employers by Science for six years. To learn more, visit www.modernatx.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, in particular concerning: the development by the Company of a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273 ); the Company’s agreement to supply the vaccine to the government of Peru; plans to obtain regulatory approval for the distribution of the vaccine in Peru; and the expected number of doses and delivery schedule of the vaccine supply. The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve risks, uncertainties and other known and unknown factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include the other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent annual report on Form 10-K filed with the State Securities and Exchange Commission (SEC). United and in subsequent filings by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility to update or revise any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210924005337/en/

CONTACT: Moderna Contacts

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

Colleen.Hussey@modernatx.com

Investors:

Lavina Talukdar

Senior Vice President and Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

KEYWORD: MASSACHUSETTS PERU UNITED STATES SOUTH AMERICA NORTH AMERICA

INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Moderna, Inc.

Copyright Business Wire 2021.

PUB: 09/24/2021 9:40 a.m. / DISC: 09/24/2021 9:42 a.m.

http://www.businesswire.com/news/home/20210924005337/en

Copyright Business Wire 2021.


Share.

Leave A Reply